Ben Hirschler

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

24 May 2018

U.S. biotechs to speed work on Nipah vaccine as virus hits India

LONDON A global coalition set up a year ago to fight epidemics has struck a $25 million deal with two U.S. biotech companies to accelerate work on a vaccine against the brain-damaging Nipah virus that has killed 12 people in India.

23 May 2018

Why the world needs more than one Ebola vaccine

LONDON - In the life-and-death race to make the first effective vaccine against Ebola, one company - Merck - seems bound to win.

21 May 2018

Roche drug dramatically reduces bleeds in key hemophilia tests

LONDON Roche's new hemophilia drug Hemlibra dramatically reduced bleeding in a broad population of hemophilia patients, results from two clinical trials showed on Monday, setting it up to take a dominant market position.

18 May 2018

Regulators flag possible birth defect link to GSK's HIV drug

LONDON U.S. and European regulators said they were assessing evidence that GlaxoSmithKline's HIV drug dolutegravir might be linked to serious birth defects, casting a shadow over a medicine that has been a key profit driver in recent years.

18 May 2018

AstraZeneca insists future is bright after big Crestor sales hit

LONDON AstraZeneca's first-quarter profit was hit by generic competition to cholesterol fighter Crestor and higher costs, but the drugmaker expects a better second half and said it remained on track for a promised return to sales growth in 2018.

18 May 2018

GSK bets on lift from new lung drugs ahead of Advair's last gasp

LONDON GlaxoSmithKline is putting more marketing muscle behind its new lung drugs and is looking for a sales boost as top respiratory experts gather to analyse clinical trials data at a meeting in San Diego this weekend.

17 May 2018

Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal

LONDON For Christophe Weber, the boss of Japan's Takeda Pharmaceutical, securing a $62 billion deal last week to buy drugmaker Shire at the fifth time of asking was the easy bit.

17 May 2018

MPs call for post-Brexit pharmaceutical deal with EU

LONDON Britain must make a continued form of membership of the European Medicines Agency (EMA) a priority to protect the pharmaceutical industry and patients after Brexit, MPs said.

10 May 2018

In Europe, Mylan's rivals try to plug EpiPen shortages

LONDON European makers of emergency allergy treatments are stepping up production of alternative life-saving adrenaline shots to try to fill intermittent shortages of Mylan's market-leading EpiPen injection.

09 May 2018

Japan's Takeda clinches $62 billion Shire deal as pharma M&A rolls on

LONDON/TOKYO Takeda Pharmaceutical agreed to buy London-listed Shire for 45.3 billion pounds ($62 billion) on Tuesday, the biggest yet in a wave of deals sweeping the drugs industry. | Video


  • Asia
  • U.S.
  • Europe
  • Sectors
Stock Search
Sensex 34,344.91 -306.33 -0.88%
Nikkei 22,689.74 -270.60 -1.18%
Hang Seng 30,665.64 -568.71 -1.82%
EUR/INR 79.916 -0.04%
USD/INR 68.310 -0.07%
GBP/INR 91.214 -0.01%
Gold 1,291.70 +0.00 +0.00%
Oil 67.50 -3.21 -4.54%
Corn 406.50 +2.25 +0.56%